Stifel 2026 Healthcare Conference 2026
Logotype for X4 Pharmaceuticals Inc

X4 Pharmaceuticals (XFOR) Stifel 2026 Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for X4 Pharmaceuticals Inc

Stifel 2026 Healthcare Conference 2026 summary

12 Nov, 2026

Operational reset and 4WARD trial

  • Refinancing and new management followed in July and August last year; costs and headcount were reduced, and the team refocused on the pivotal 4WARD trial.

  • Planned enrollment was reduced from 176 to 126, retaining 89% power for the infection endpoint and 93% for ANC; blinded baseline characteristics supported the change.

  • Parexel partnership improved trial operations; recent months brought the strongest screening-to-randomization dynamics to date.

  • Enrollment is targeted to close by year-end 2026, with topline phase III chronic neutropenia data expected in Q1 2028.

  • Trial assumptions include ~1/3 lower infection rate and at least 1/3 of patients achieving an ANC increase of 500 cells/µL on at least 3 occasions over 12 months.

Clinical evidence and safety

  • Blinded baseline profile: median age 36; 68% had at least 3 infections, versus 2 required for enrollment; ~37% were receiving G-CSF.

  • Small phase II dataset showed mavorixafor could normalize ANC in patients with low counts and allow G-CSF dose reduction in patients with higher ANC; ~70% overall reduced G-CSF, with some stopping it.

  • A blinded independent committee, including hematology and infectious disease specialists, adjudicates infections; minor mouth ulcers do not qualify, and blinded events were tracking as expected.

  • No new safety signals had emerged with longer exposure; reported GI toxicity can be treated symptomatically and appears to resolve after a couple of weeks.

Market opportunity and commercial outlook

  • Expected label base case: symptomatic chronic neutropenia, with claims related to reducing infections and their severity or duration; a broader symptomatic label could expand the opportunity from 15,000 to 30,000 patients.

  • Market research indicated 95,000 patients with primary chronic neutropenia, 30,000 symptomatic patients, and 15,000 with at least 2 infections; claims, physician surveys, patient input, and advisory boards informed estimates.

  • In 2025, 6,300 patients were hospitalized with the condition, with a median stay of 4 days; severely neutropenic patients, including those with ANC below 1,000, were highlighted as an initial treatment focus.

  • A personal pricing estimate was $250,000-$350,000 per year, versus $585,000 per year for WHIM, which was viewed as unsustainable for the larger market.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from X4 Pharmaceuticals